Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Putnam Global Health Care R PHSRX
- NAV / 1-Day Return 54.42 / −0.04 %
- Total Assets 1.7 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.320%
- Distribution Fee Level Below Average
- Share Class Type Retirement, Medium
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield —
- Turnover 41%
USD | NAV as of May 03, 2024 | 1-Day Return as of May 03, 2024, 10:17 PM GMT+0
Morningstar’s Analysis PHSRX
Will PHSRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 58.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
UnitedHealth Group Inc | 8.30 | 147.2 Mil | Healthcare |
Eli Lilly and Co | 7.68 | 136.3 Mil | Healthcare |
AbbVie Inc | 7.59 | 134.6 Mil | Healthcare |
Intuitive Surgical Inc | 6.08 | 107.9 Mil | Healthcare |
AstraZeneca PLC | 5.62 | 99.6 Mil | Healthcare |
Novo Nordisk A/S Class B | 5.09 | 90.4 Mil | Healthcare |
Boston Scientific Corp | 5.05 | 89.6 Mil | Healthcare |
Thermo Fisher Scientific Inc | 4.55 | 80.7 Mil | Healthcare |
Innoviva Inc | 4.41 | 78.3 Mil | Healthcare |
Ascendis Pharma A/S ADR | 4.34 | 77.0 Mil | Healthcare |